BioSpace News Archive

CytoSorbents Corporation announced that it has received $5 million in non-dilutive debt financing under the terms of the Fourth Amendment to its Amended and Restated Loan and Security Agreement with Bridge Bank, which provided for a term loan commitment of up to $15 million in aggregate, available for drawdown in tranches of $5 million each at the discretion of CytoSorbents and subject to certain financial requirements.

TransCode Therapeutics, Inc., the RNA Oncology Company™ committed to more effectively treating cancer using RNA therapeutics, announced that it has received written authorization from the U.S. Food and Drug Administration that it may proceed with its First-in-Human Phase 0 clinical trial.

Neogen Corporation announced that the Company will participate in the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, California, on Wednesday, January 11, 2023.

Hoth Therapeutics, Inc. announced that the U.S. Food and Drug Administration has accepted an Investigational New Drug application for the company’s HT-001 therapeutic for the treatment for rash and skin disorders associated with epidermal growth factor receptor inhibitor therapy.

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced its unaudited financial results for the six months ended June 30, 2022.

Alterity Therapeutics, a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, announced that a new composition of matter patent has been allowed by the United States Patent and Trademark Office.

Complete Genomics Inc announced that it is presenting at Biotech Showcase™ 2023, taking place in San Francisco at the same time as the JP Morgan healthcare conference.

ABM Respiratory Care, a medical technology company focused on developing and globally commercializing novel integrated airway clearance and ventilation solutions, announced the U.S. Food and Drug Administration 510 clearance of the BiWaze® Clear System.

Neuronetics, Inc. announced the appointment of Joseph H. Capper to its Board of Directors and as a member of the Audit Committee effective January 1, 2023.

Sesen Bio, Inc. and Carisma Therapeutics Inc., a privately-held, clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced an amendment to their previously announced merger agreement dated September 20, 2022.